New findings from Phase 2 adjunctive study evaluating the characteristics of OFF time improvement with solengepras, a novel, non-dopaminergic ...

Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced that it has initiated a Phase 1 study of its lead candidate, ...

Symptoms of Parkinson’s disease, such as tremors and stiffness, can make daily tasks difficult. A new drug has shown promise in alleviating symptoms. Tavapadon, a drug being tested to treat early ...

A new study shows how failing mitochondria and rising oxidative stress may set off key steps in Parkinson’s disease.

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

A test that can detect Parkinson's disease in the early stages of the illness has moved a step closer. Scientists have developed a way of detecting a molecule linked to the condition in samples of ...

For years, researchers have watched the tiny power plants inside brain cells falter in Parkinson’s disease and wondered what ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...

In Parkinson’s disease, early signs such as constipation, loss of smell, and REM sleep disturbance may appear up to a decade ...

New findings from Phase 2 adjunctive study evaluating the characteristics of OFF time improvement with solengepras, a novel, non-dopaminergic GPR6 inhibitor; poster selected as one of 10 featured sele ...